The effect of parenteral L- carnitine on patients with COVID-19

Phase 2

Conditions: COVID _19.
Coronavirus infection, unspecified
B34.2

Registration Number: IRCT20170609034406N10

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 100

Inclusion Criteria

adults aged 18 years or older
Positive PCR test for COVID-19
Patients with moderate to severe disease
Signs and Symptoms compatible with COVID-19 disease according to the Iranian Ministry of Health protocol
Prior to the fifth day of symptoms onset

Exclusion Criteria

Pregnancy
Lactation
HIV Infection
History of taking L-carnitine supplement in the recent Month
known immunosuppression condition or any active malignancy
Patients with hypothyroidism or hyperthyroidism
patients with regular aerobic training (more than 3 times a week with further than 2 hours each time)
History of allergy to L-carnitine or its analogues
History of or an increased risk for seizure

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The length of hospitalization. Timepoint: At the end of study. Method of measurement: Comparing the number of hospitalization days between the intervention group and control group.;Disease severity. Timepoint: Daily. Method of measurement: Disease Severity Checklist in NIH Guidelines.;Mortality. Timepoint: End of study. Method of measurement: Patient file.;Time to improve clinical symptoms. Timepoint: Daily. Method of measurement: Questionnaire.

Secondary Outcome Measures

Name	Time	Method
Serum Ferritin level. Timepoint: At the beginning and end of the study. Method of measurement: Ferritin kit.;Serum LDH (Lactate Dehydrogenase) level. Timepoint: At the beginning and end of the study. Method of measurement: Alkaline phosphatase Assay Kit (DGKC Kit).;Serum D_dimer level. Timepoint: At the beginning and end of the study. Method of measurement: D_dimer ELISA kit.;Serum C_ reactive protein (CRP) level. Timepoint: At the beginning and end of the study. Method of measurement: CRP ELISA Kit.;Oxygen saturation. Timepoint: Daily. Method of measurement: oxymeter.;Require for mechanical ventilation. Timepoint: daily. Method of measurement: observation.;L-carnitine serum level. Timepoint: baseline and end of the study. Method of measurement: ELISA kit.